Search research articles
Contact Us
Filters
Showing results (361-370 of 493) with videos related to
Page
of 50
Sort By:
Oncotarget
|
December 22, 2017
Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression
Aly-Khan A Lalani, Kathryn P Gray, Laurence Albiges, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 8, 2010
Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma
Kazuo Koyanagi, Steven J O'Day, Peter Boasberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 22, 2014
Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group
Lawrence E Flaherty, Megan Othus, Michael B Atkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2008
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
Edward L Korn, Ping-Yu Liu, Sandra J Lee, et al.
Cancer Immunology Research
|
May 28, 2015
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
Marcella Callea, Laurence Albiges, Mamta Gupta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 1, 1997
Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity
J A Sosman, F R Aronson, M Sznol, et al.
Journal for Immunotherapy of Cancer
|
September 12, 2025
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047
Meredith M Regan, Paolo A Ascierto, Evan J Lipson, et al.
The Lancet. Oncology
|
December 11, 2012
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study
Fabio A B Schutz, Mark M Pomerantz, Kathryn P Gray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 10, 2008
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma
Jeffrey A Sosman, Carole Carrillo, Walter J Urba, et al.
Journal for Immunotherapy of Cancer
|
March 31, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
Jarushka Naidoo, Catherine Murphy, Michael B Atkins, et al.
Page
of 50
Search research articles
Search
Showing results (361-370 of 493) with videos related to
Sort By:
Page
of 50
Oncotarget
|
December 22, 2017
Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression
Aly-Khan A Lalani, Kathryn P Gray, Laurence Albiges, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 8, 2010
Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma
Kazuo Koyanagi, Steven J O'Day, Peter Boasberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 22, 2014
Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group
Lawrence E Flaherty, Megan Othus, Michael B Atkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2008
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
Edward L Korn, Ping-Yu Liu, Sandra J Lee, et al.
Cancer Immunology Research
|
May 28, 2015
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
Marcella Callea, Laurence Albiges, Mamta Gupta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 1, 1997
Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity
J A Sosman, F R Aronson, M Sznol, et al.
Journal for Immunotherapy of Cancer
|
September 12, 2025
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047
Meredith M Regan, Paolo A Ascierto, Evan J Lipson, et al.
The Lancet. Oncology
|
December 11, 2012
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study
Fabio A B Schutz, Mark M Pomerantz, Kathryn P Gray, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 10, 2008
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma
Jeffrey A Sosman, Carole Carrillo, Walter J Urba, et al.
Journal for Immunotherapy of Cancer
|
March 31, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
Jarushka Naidoo, Catherine Murphy, Michael B Atkins, et al.
Page
of 50